Nasdaq Grants Profusa Transfer to Capital Market, Averting Immediate Delisting
PFSA sits 23% above its 52-week low of $0.41.
Summary
Profusa, Inc. received a favorable determination from the Nasdaq Hearings Panel, allowing the company to transfer its listing from The Nasdaq Global Market to The Nasdaq Capital Market. This decision provides a crucial reprieve following the delisting notice received on April 29, 2026, which cited failure to meet minimum market value requirements. The continued listing is conditional on Profusa satisfying certain interim milestones and achieving compliance with bid price and stockholders' equity requirements for the Capital Market tier by July 6, 2026. This development is significant for the micro-cap company, as it avoids immediate delisting and buys time to address its underlying financial and compliance issues, which have been highlighted by recent dilutive financing and a going concern warning in its 10-K. Traders will now watch for the company's progress towards meeting the new listing requirements by the July deadline.
At the time of this announcement, PFSA was trading at $0.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $0.41 to $975.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.